SpliceBio collaborates with Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease
SpliceBio, a Barcelona, Spain-based genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has signed an exclusive collaboration and licensing agreement with Philadelphia, Pennsylvania-based Spark Therapeutics to utilize SpliceBio’s proprietary protein splicing platform to develop a gene therapy for an undisclosed inherited retinal disease.